ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home ICI

Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy

on: June 23, 2020In: Meeting News
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor
            Therapy

By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) […] Read more


PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

on: April 15, 2020In: Diagnostic Oncology
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more

Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About the Management of Immunotherapy AEs

on: February 11, 2020In: Nursing & Allied Health
Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About the Management of
            Immunotherapy AEs

By Enza Esposito Nguyen, DNP, RN, ANP-BC Posted: February 12, 2020   Dr. Enza Esposito Nguyen Although we continue to see many immunotherapy clinical trials mature and deliver marvelous improvements […] Read more

Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

on: February 11, 2020In: Systemic, Targeted, & Immune Therapies
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status.   […] Read more

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

on: December 10, 2019In: Uncategorized
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated […] Read more

Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data

on: December 10, 2019In: Evolving Standards of Care
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational
            Data

Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. […] Read more

IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy